Table 1.
Clinical characteristics of patients with molecularly defined AGCT
| Characteristic | Total | Finland | Netherlands | Germany | P† |
|---|---|---|---|---|---|
| Age at last birthday, y | |||||
| Median (IQR) | 54 (45–61) | 54 (44–62) | 52 (45–58) | 57 (47–70) | .28 |
| Stage (FIGO 2009), No. (%) | |||||
| Stage I | 218 (85.2) | 148 (90.2) | 46 (76.7) | 24 (75.0) | .03 |
| I | 11 (4.3) | 6 (3.7) | 5 (8.3) | 0 (0) | .002 |
| Ia | 130 (50.8) | 88 (53.7) | 21 (35.0) | 21 (65.6) | |
| Ib | 4 (1.6) | 1 (0.6) | 2 (3.3) | 1 (3.1) | |
| Ic | 73 (28.5) | 53 (32.3) | 18 (30.0) | 2 (6.2) | |
| Stage II | 23 (9.0) | 10 (6.1) | 8 (13.3) | 5 (15.6) | |
| Stage III | 10 (3.9) | 3 (1.8) | 4 (6.7) | 3 (9.4) | |
| Unknown | 5 (2.0) | 3 (1.8) | 2 (3.3) | 0 (0) | |
| Type of surgery, No. (%) | <.001 | ||||
| HYS+BSO | 157 (61.3) | 112 (68.3) | 26 (43.3) | 19 (59.4) | |
| USO | 66 (25.8) | 31 (18.9) | 28 (46.7) | 7 (21.9) | |
| BSO | 26 (10.2) | 14 (8.5) | 6 (10.0) | 6 (18.6) | |
| Other/unknown | 5 (2.0) | 5 (3.0) | 0 (0.0) | 0 (0) | |
| Any adjuvant treatment*, No. (%) | .15 | ||||
| Yes | 52 (20.3) | 40 (24.4) | 8 (13.3) | 4 (12.5) | |
| No | 197 (77.0) | 123 (75.0) | 52 (86.7) | 22 (68.8) | |
| Unknown | 7 (2.7) | 1 (0.6) | 0 (0.0) | 6 (18.8) | |
| Follow-up time, y | |||||
| Reverse KM | 10.49 | 14.32 | 8.96 | 5.34 | |
| OS (95% CI), % | |||||
| 5-y | 93.3 (91.5 to 98.4) | 94.9 (91.5 to 98.4) | 92.6 (85.8 to 99.9) | 85.2 (72.7 to 99.8) | |
| 10-y | 84.4 (79.5 to 89.5) | 89.8 (81.4 to 92.5) | 80.5 (69.7 to 91.3) | 79.5 (64.6 to 98.0) | |
| 15-y | 72.1 (65.6 to 79.2) | 77.0 (70.0 to 84.7) | 59.4 (44.7 to 79.1) | 39.8 (9.8 to 100) | |
| Deaths, No. (%) | .07 | ||||
| Yes | 92 (35.9) | 65 (39.6) | 6 (18.8) | 21 (35.0) | |
| No | 164 (64.1) | 99 (60.4) | 26 (81.2) | 39 (65.0) | |
| DSS (95% CI), % | |||||
| 5-y | 97.4 (95.3 to 99.5) | 98.6 (96.8 to 100) | 94.6 (88.9 to 100) | 95.5 (87.1 to 100) | |
| 10-y | 91.8 (88.0 to 95.8) | 93.2 (88.9 to 97.6) | 87.4 (78.3 to 97.5) | 95.5 (87.1 to 100) | |
| 15-y | 85.4 (80.0 to 91.2) | 89.0 (83.5 to 95.0) | 71.9 (57.6 to 89.7) | 95.5 (87.1 to 100) | |
| Deaths of disease, No. (%) | .01 | ||||
| Yes | 42 (16.4) | 25 (15.2) | 1 (3.1) | 16 (26.7) | |
| No | 213 (83.2) | 138 (84.1) | 31 (96.9) | 44 (73.3) | |
| Unknown | 1 (0.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | |
| Number of patients with recurrent disease, No. (%) | <.001 | ||||
| Yes | 90 (35.2) | 46 (28.0) | 38 (63.3) | 6 (18.8) | |
| No | 143 (55.9) | 110 (67.1) | 20 (33.3) | 13 (40.6) | |
| Unknown | 23 (9.0) | 8 (4.9) | 2 (3.3) | 13 (40.6) | |
| Time to event for patients who recurred, median, y | |||||
| OS | 13.4 | 16.5 | 3.2 | 11.6 | |
| DSS | 12.7 | 14.7 | 3.3 | 12.5 | |
| RFS | 13.9 | 7.2 | 4.2 | 5.3 | |
*Includes chemotherapy and radiation. The percentages shown are reflected in the column groupings. BSO = bilateral salpingo-oophorectomy; CI = confidence interval; DSS = disease-specific survival; HYS = hysterectomy; IQR = interquartile range; OS = overall survival; RFS = relapse-free survival; USO = unilateral salpingo-oophorectomy.
†All P values are two-sided and calculated using the Fisher’s exact test to assess associations with categorical variables, and t tests were used for continuous ones.